The European Union approved GSK's ADC Blenrep (belantamab mafodotin) on 24 July for use with bortezomib/dexamethasone (BVd) or pomalidomide/dexamethasone (BPd) in relapsed/refractory multiple myeloma (r/r MM) patients after at least one prior line of therapy. The decision was based on Phase III DREAMM-7 and DREAMM-8 trials showing BVd tripled median progression-free survival (mPFS) versus daratumumab-based regimens (36.6 vs 13.4 months) and reduced death risk by 42%.

Blenrep’s ocular side effects proved manageable, with ≤9% discontinuation rates. The BCMA-targeted therapy is now approved in the UK, Japan and Canada, with US and China reviews ongoing.

According to PharmCube's NextBiopharm® database, Blenrep is being developed for three other blood-related diseases. Click here to request a free trial for NextBiopharm®.